Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Clarithromycin

Aliases
Biaxin, Clarithromycin 500mg, Clarithromycin placebo tablets, Clarithromycin tablets (1 other aliases)
Name
Clarithromycin
INN Name
Clarithromycin
FDA Approved
Yes

37 clinical trials

30 organizations

37 indications

1 document

Indication
Healthy
Indication
Drug-drug interactions
Indication
Healthy Adults
Indication
Helicobacter pylori infection
Indication
Multiple Myeloma
Indication
Healthy Control Participants
Indication
Helicobacter pylori
Indication
Safety Issues
Indication
pharmacokinetics
Indication
Drug Interaction
Indication
Tolerability
Indication
B-cell Lymphoma
Indication
Gastritis
Indication
Dyspepsia
Indication
Stomach Cancer
Indication
Peptic Ulcer
Indication
Community-acquired Pneumonia
Indication
Sepsis
Indication
Inflammatory Response
Indication
Mortality
Indication
Biomarkers
Indication
systemic inflammatory response syndrome
Indication
Pulmonary Disease Due to Mycobacteria
Indication
Preterm Premature Rupture of Membrane
Indication
Pregnancy
Indication
High-risk
Indication
premature birth
Indication
Narcolepsy Without Cataplexy
Indication
Idiopathic Hypersomnia
Indication
narcolepsy with cataplexy
Indication
Drug-induced QT prolongation
Indication
pharmacodynamics
Indication
Vitamin D and Calcium Homeostasis
Indication
Relapsed Multiple Myeloma
Indication
Mycobacterium Avium Complex-lung Disease (MAC-LD)
Indication
Pneumonia
Indication
Mycobacterium Avium Complex
Clinical trial
An Open-label, Fixed-sequence, Phase 1 Clinical Trial to Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults
Status: Completed, Estimated PCD: 2023-11-06
Clinical trial
An Open-label, Single-center, Study in Healthy Subjects to Investigate the Effect of Oral Clarithromycin on the Pharmacokinetics of Givinostat (PART 2)
Status: Completed, Estimated PCD: 2022-05-08
Clinical trial
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection
Status: Completed, Estimated PCD: 2024-03-26
Clinical trial
An Open-label Study to Determine the Effect of Oral Doses of KP-001 on Metformin and Midazolam Pharmacokinetics After a Single Oral Administration and to Determine the Effect of Clarithromycin on KP-001 Pharmacokinetics After a Single Oral Administration in Healthy Adult Participants
Status: Active (not recruiting), Estimated PCD: 2024-03-15
Clinical trial
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2027-04-01
Clinical trial
A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants
Status: Completed, Estimated PCD: 2022-11-03
Clinical trial
An Open-label, Fixed-sequence Study to Evaluate the Drug-drug Interactions Between Tegoprazan Tablets and Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, and Clarithromycin Tablets in Healthy Subjects
Status: Completed, Estimated PCD: 2023-04-28
Clinical trial
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Subjects
Status: Completed, Estimated PCD: 2023-09-22
Clinical trial
Effect of Repeated Dosing of Clarithromycin on PK of Linaprazan Glurate/Linaprazan, Effect of Single Dose of Linaprazan Glurate on PK of Clarithromycin, Single/Repeated Dosing of Linaprazan Glurate on PK of Midazolam to Healthy Subjects
Status: Completed, Estimated PCD: 2023-05-30
Clinical trial
A Randomized Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral TAK-438 20 mg Compared to Esomeprazole 20 mg Twice Daily in Subjects With Helicobacter Pylori Infection
Status: Completed, Estimated PCD: 2021-11-01
Clinical trial
A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With Vonoprazan Versus Quadruple Therapy With Esomeprazole
Status: Completed, Estimated PCD: 2021-09-27
Clinical trial
A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies
Status: Completed, Estimated PCD: 2022-02-21
Clinical trial
EU4Health Project Eurohelican: A Single-center Prospective Feasibility Study of the Proposed Test-and-treat Preventive Screening Program in Younger Slovenian Participants Aged 30-34 Years With or Without Helicobacter Pylori Infection
Status: , Estimated PCD: 2024-12-01
Clinical trial
A "Screen and Treat" Helicobacter Pylori Eradication Trial in 14-18 Years Old Adolescents Residing in Three Regions of Chile: Effectiveness and Microbiological-host Implications
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
Status: Recruiting, Estimated PCD: 2023-12-02
Clinical trial
Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians
Status: Completed, Estimated PCD: 2021-03-16
Clinical trial
A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
A Randomized Clinical Trial of Oral Clarithromycin in Community-acquired Pneumonia to Attenuate Inflammatory Responses and Improve Outcomes: the ACCESS Clinical Trial
Status: Completed, Estimated PCD: 2023-04-11
Clinical trial
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT)
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days
Status: Completed, Estimated PCD: 2023-05-30
Clinical trial
Phase I/II Study of Ixazomib in Combination With Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients With Double Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Improvement of PPROM Management With Prophylactic Antimicrobial Therapy
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis
Status: Completed, Estimated PCD: 2023-06-13
Clinical trial
Effect of Modulating CYP3A4 Activity on Mineral Homeostasis
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2016-06-07
Clinical trial
Randomized Single Dose Crossover Replicate Comparative Bioavailability Study of Clarithromycin 250 mg Tablets in Healthy Male and Female Volunteers Under Fasted Conditions
Status: Completed, Estimated PCD: 2004-06-01
Clinical trial
Efficacy and Safety of Berberine Hydrochloride, Amoxicillin and Rabeprazole Triple Therapy in the First Eradication of Helicobacter Pylori
Status: Completed, Estimated PCD: 2021-12-20
Clinical trial
Study on The Efficacy and Safety of Berberine,Amoxicillin and Vonoprazan Containing Triple Therapy in Helicobacter Pylori First-Line Eradication
Status: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Status: Recruiting, Estimated PCD: 2025-09-23
Clinical trial
Lenalidomide and Dexamethasone (Rd) Versus Clarithromycin [Biaxin®] / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-06-22
Clinical trial
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Ten-day Amoxicillin-containing Dual Therapy as First-line Helicobacter Pylori Treatment in Elderly Patients: a Randomized Trial
Status: , Estimated PCD: 2023-08-01
Clinical trial
High-Dose Dual Therapy vs Standard Triple Therapy for Treatment-Naïve H. Pylori: A Prospective Randomized Control Trial in a Diverse Urban New York City Population
Status: Completed, Estimated PCD: 2022-01-01
Clinical trial
Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection
Status: Recruiting, Estimated PCD: 2024-03-01
Document
DailyMed Label: Clarithromycin
Organization
Rebel Distributors Corp.
Organization
Lannett Company, Inc.
Organization
RedPharm Drug, Inc.
Organization
A-S Medication Solutions
Organization
PD-Rx Pharmaceuticals, Inc.
Organization
American Health Packaging
Organization
RPK Pharmaceuticals, Inc.
Organization
Chartwell RX, LLC.
Organization
AvPAK
Organization
Aurobindo Pharma Limited
Organization
REMEDYREPACK INC.
Organization
Alembic Pharmaceuticals Inc.
Organization
Alembic Pharmaceuticals Limited
Organization
Major Pharmaceuticals
Organization
NuCare Pharmaceuticals, Inc.
Organization
Strides Pharma Science Limited
Organization
DirectRx
Organization
NuCare Pharmaceuticals,Inc.
Organization
Direct_Rx
Organization
Actavis Pharma, Inc.
Organization
Preferred Pharmaceuticals Inc.
Organization
bryant ranch prepack
Organization
Proficient Rx LP
Organization
Sandoz Inc.
Organization
Preferred Pharmaceuticals Inc. USA
Organization
Northwind Pharmaceuticals, LLC
Organization
Chartwell RX, LLC
Organization
Rising Pharma Holdings, Inc.
Organization
Ajanta Pharma USA Inc.
Organization
Ranbaxy Pharmaceuticals Inc.